These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 21883030

  • 1. Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.
    Minarik J, Scudla V, Tichy T, Pika T, Bacovsky J, Lochman P, Zadrazil J.
    Leuk Lymphoma; 2012 Feb; 53(2):330-1. PubMed ID: 21883030
    [No Abstract] [Full Text] [Related]

  • 2. Managing light chain deposition disease.
    Gertz MA.
    Leuk Lymphoma; 2012 Feb; 53(2):183-4. PubMed ID: 21913808
    [No Abstract] [Full Text] [Related]

  • 3. Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.
    Siniscalchi A, Dentamaro T, Perrotti A, Tatangelo P, de Fabritiis P, Caravita T.
    Ann Hematol; 2010 Aug; 89(8):821-2. PubMed ID: 19953253
    [No Abstract] [Full Text] [Related]

  • 4. Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment.
    Szturz P, Adam Z, Vašků V, Feit J, Krejčí M, Pour L, Hájek R, Mayer J.
    Leuk Lymphoma; 2013 Jun; 54(6):1324-6. PubMed ID: 23061634
    [No Abstract] [Full Text] [Related]

  • 5. Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure.
    Gharwan H, Truica CI.
    Med Oncol; 2012 Jun; 29(2):1197-201. PubMed ID: 21479696
    [Abstract] [Full Text] [Related]

  • 6. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
    Zannetti BA, Zamagni E, Santostefano M, De Sanctis LB, Tacchetti P, Mancini E, Pantani L, Brioli A, Rizzo R, Mancuso K, Rocchi S, Pezzi A, Borsi E, Terragna C, Marzocchi G, Santoro A, Cavo M.
    Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
    [Abstract] [Full Text] [Related]

  • 7. Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
    Yuan ZG, Dun XY, Li YH, Hou J.
    J Hematol Oncol; 2009 Apr 28; 2():19. PubMed ID: 19400935
    [Abstract] [Full Text] [Related]

  • 8. Successful bone reconstruction after bortezomib therapy in a myeloma patient.
    Tanaka T, Yamasaki R, Omura H, Hino N.
    Int J Hematol; 2011 Sep 28; 94(3):221. PubMed ID: 21861100
    [No Abstract] [Full Text] [Related]

  • 9. Diagnosis and the current trends in multiple myeloma therapy.
    Dmoszyńska A.
    Pol Arch Med Wewn; 2008 Oct 28; 118(10):563-6. PubMed ID: 19112817
    [Abstract] [Full Text] [Related]

  • 10. Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib.
    Khan AA, Siraj F, Bhargava M, Aggarwal S.
    BMJ Case Rep; 2012 Dec 20; 2012():. PubMed ID: 23264156
    [Abstract] [Full Text] [Related]

  • 11. Drug pricing: No cure, no cost.
    Jack A.
    BMJ; 2007 Jul 21; 335(7611):122-3. PubMed ID: 17641343
    [Abstract] [Full Text] [Related]

  • 12. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.
    Qayum A, Aleem A, Al Diab AR, Niaz F, Al Momen AK.
    Saudi J Kidney Dis Transpl; 2010 Jan 21; 21(1):63-8. PubMed ID: 20061695
    [Abstract] [Full Text] [Related]

  • 13. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
    Muta T, Nakanishi H, Yasunaga M, Senba S, Murakami H, Kan S, Ueda Y, Fujisaki T.
    Gan To Kagaku Ryoho; 2011 Feb 21; 38(2):237-41. PubMed ID: 21368487
    [Abstract] [Full Text] [Related]

  • 14. Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.
    Wondergem MJ, Grünberg K, Wittgen BP, Sonneveld P, Zweegman S.
    Histopathology; 2009 Apr 21; 54(5):631-3. PubMed ID: 19302537
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
    Federico V, Breccia M, Petrucci MT, Loglisci G, Mansueto G, Mercanti C, Levi A, Cartoni C, Musto P, Alimena G.
    Clin Adv Hematol Oncol; 2012 Apr 21; 10(4):266-8. PubMed ID: 22706491
    [No Abstract] [Full Text] [Related]

  • 16. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
    Wang HH, Tsui J, Wang XY, Liu SS, Li J.
    Leuk Lymphoma; 2014 Jun 21; 55(6):1404-5. PubMed ID: 23927397
    [No Abstract] [Full Text] [Related]

  • 17. Renal improvement in myeloma with bortezomib plus plasma exchange.
    Burnette BL, Leung N, Rajkumar SV.
    N Engl J Med; 2011 Jun 16; 364(24):2365-6. PubMed ID: 21675906
    [No Abstract] [Full Text] [Related]

  • 18. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
    Hrusovsky I, Emmerich B, von Rohr A, Voegeli J, Taverna C, Olie RA, Pliskat H, Frohn C, Hess G.
    Oncology; 2010 Jun 16; 79(3-4):247-54. PubMed ID: 21372599
    [Abstract] [Full Text] [Related]

  • 19. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
    Mele G, Pinna S, Alloro E, Brocca MC, Coppi MR, Quarta G.
    Leuk Res; 2007 May 16; 31(5):721-3. PubMed ID: 16890285
    [No Abstract] [Full Text] [Related]

  • 20. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
    Kaposztas Z, Kahan BD, Katz SM, Van Buren CT, Cherem L.
    Transplant Proc; 2009 Dec 16; 41(10):4407-10. PubMed ID: 20005409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.